These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

420 related articles for article (PubMed ID: 20603408)

  • 41. Radiobiological equivalent of low/high dose rate brachytherapy and evaluation of tumor and normal responses to the dose.
    Manimaran S
    Radiat Med; 2007 Jun; 25(5):229-35. PubMed ID: 17581712
    [TBL] [Abstract][Full Text] [Related]  

  • 42. New challenges in high-energy particle radiobiology.
    Durante M
    Br J Radiol; 2014 Mar; 87(1035):20130626. PubMed ID: 24198199
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Redefining relative biological effectiveness in the context of the EQDX formalism: implications for alpha-particle emitter therapy.
    Hobbs RF; Howell RW; Song H; Baechler S; Sgouros G
    Radiat Res; 2014 Jan; 181(1):90-8. PubMed ID: 24502376
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The assessment of RBE effects using the concept of biologically effective dose.
    Dale RG; Jones B
    Int J Radiat Oncol Biol Phys; 1999 Feb; 43(3):639-45. PubMed ID: 10078651
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The Radiobiology of Proton Therapy: Challenges and Opportunities Around Relative Biological Effectiveness.
    Jones B; McMahon SJ; Prise KM
    Clin Oncol (R Coll Radiol); 2018 May; 30(5):285-292. PubMed ID: 29454504
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Radiobiology for eye plaque brachytherapy and evaluation of implant duration and radionuclide choice using an objective function.
    Gagne NL; Leonard KL; Rivard MJ
    Med Phys; 2012 Jun; 39(6):3332-42. PubMed ID: 22755715
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A generalised method for calculating repopulation-corrected tumour EQD2 values in a wide range of clinical situations, including interrupted treatments.
    Dale R; Plataniotis G; Jones B
    Phys Med; 2024 Feb; 118():103294. PubMed ID: 38199178
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Predicting realistic RBE values for clinically relevant radiotherapy schedules.
    Denekamp J; Waites T; Fowler JF
    Int J Radiat Biol; 1997 Jun; 71(6):681-94. PubMed ID: 9246183
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Monte Carlo radiotherapy simulations of accelerated repopulation and reoxygenation for hypoxic head and neck cancer.
    Harriss-Phillips WM; Bezak E; Yeoh EK
    Br J Radiol; 2011 Oct; 84(1006):903-18. PubMed ID: 21933980
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Optimization of radiobiological effects in intensity modulated proton therapy.
    Wilkens JJ; Oelfke U
    Med Phys; 2005 Feb; 32(2):455-65. PubMed ID: 15789592
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Is the dose-averaged LET a reliable predictor for the relative biological effectiveness?
    Grün R; Friedrich T; Traneus E; Scholz M
    Med Phys; 2019 Feb; 46(2):1064-1074. PubMed ID: 30565705
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The impact on oncology of the interaction of radiation therapy and radiobiology.
    Pedraza Muriel V
    Clin Transl Oncol; 2006 Feb; 8(2):83-93. PubMed ID: 16632421
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Constraints in the use of repair half times and mathematical modelling for the clinical application of HDR and PDR treatment schedules as an alternative for LDR brachytherapy.
    Pop LA; van den Broek JF; Visser AG; van der Kogel AJ
    Radiother Oncol; 1996 Feb; 38(2):153-62. PubMed ID: 8966228
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Tracks to therapy.
    Katz R; Cucinotta FA
    Radiat Meas; 1999 Jun; 31(1-6):379-88. PubMed ID: 12025838
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Individualizing cancer treatment: biological optimization models in treatment planning and delivery.
    Brahme A
    Int J Radiat Oncol Biol Phys; 2001 Feb; 49(2):327-37. PubMed ID: 11173125
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A radiobiological model for the relative biological effectiveness of high-dose-rate 252Cf brachytherapy.
    Rivard MJ; Melhus CS; Zinkin HD; Stapleford LJ; Evans KE; Wazer DE; Odlozilíková A
    Radiat Res; 2005 Sep; 164(3):319-23. PubMed ID: 16137205
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Introducing Proton Track-End Objectives in Intensity Modulated Proton Therapy Optimization to Reduce Linear Energy Transfer and Relative Biological Effectiveness in Critical Structures.
    Traneus E; Ödén J
    Int J Radiat Oncol Biol Phys; 2019 Mar; 103(3):747-757. PubMed ID: 30395906
    [TBL] [Abstract][Full Text] [Related]  

  • 58. THE ROLE OF PARTICLE SPECTRA IN MODELING THE RELATIVE BIOLOGICAL EFFECTIVENESS OF PROTON RADIOTHERAPY BEAMS.
    Grzanka L; Waligórski MPR; Bassler N
    Radiat Prot Dosimetry; 2019 May; 183(1-2):251-254. PubMed ID: 30566667
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The radiobiology of conventional radiotherapy and its application to radionuclide therapy.
    Dale R; Carabe-Fernandez A
    Cancer Biother Radiopharm; 2005 Feb; 20(1):47-51. PubMed ID: 15778580
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Radical radiotherapy for invasive bladder cancer: What dose and fractionation schedule to choose?
    Pos FJ; Hart G; Schneider C; Sminia P
    Int J Radiat Oncol Biol Phys; 2006 Mar; 64(4):1168-73. PubMed ID: 16376486
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.